Cambridge University Health Partners and the Milner Therapeutics Institute launched a new partnership with Flagship Pioneering in 2025. This is the first Flagship partnership in Europe and reflects their vision to work more extensively in the UK following the establishment of Quotient Therapeutics here in Cambridge.
The collaboration will focus on research and innovation and will enable Flagship Pioneering’s ecosystem of more than 40 companies to partner with Cambridge academics and clinicians to drive breakthrough science and technologies. There will be a strong emphasis on leveraging the complementary expertise and capabilities here in Cambridge to build collaborations with existing portfolio companies. These will span multiple areas of biology, technology, drug discovery stage & modality and aim to unlock value for all parties, including:
- Consultancy roles, including subject matter expertise or experimental capabilities
- Roles on advisory boards
- Partnerships around access to datasets or samples (blood, tissue), technology validation
- Clinical translation
- Co-creative research collaborations e.g. around technology, modality, assay or disease model development, or hypothesis generation around mechanisms of disease
In addition to these partnerships, Flagship colleagues (including those based in the new London office) are keen to bring their perspective and experience in entrepreneurship to the Cambridge ecosystem, offering mentoring and in-kind support for training initiatives.
Through this new partnership, Flagship will explore exciting opportunities across other top organizations in the Cambridge life sciences ecosystem, including the Wellcome Sanger Institute, the MRC Laboratory of Molecular Biology, the Babraham Institute, University of Cambridge, the NIHR Cambridge Biomedical Research Centre, the NIHR Cambridge Clinical Research Facility, and the Cambridge University Hospitals NHS Trust.
Get in Touch
Academic teams are encouraged to contact Nadia Arnaudo, Partnership Manager, for further information on how to engage with Flagship companies. Upcoming events can be found on the Milner web calendar.
About Flagship Pioneering
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.